Search Results - "Peacock, Nancy Walker"

Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US by Razavi, Pedram, Ahmed, Mehnaj, Roush, Ashley, Parikh, Rohan, Hitchens, Abigail, Shen, Sherry, Safonov, Anton, Jhaveri, Komal L., Robson, Mark E., Peacock, Nancy Walker, Ma, Yanjun, Santarsiero, Elizabeth Chertow, Ganapathy, Vaidyanathan, Shah, Rohan M., Amefule, Adaeze Q., Lteif, Agnes, Blakely, L. Johnetta

“…e12533 Background: Despite improved management of HR+/HER2− EBC, pts experience recurrences while on or up to decades after ending standard-of-care (SOC) ET…”
Get full text

Care coordination for oral oncolytics through pharmacy integration and cycle 1-day 1 documentation by Peacock, Nancy Walker, McCullough, Stacey, Crumb, Jared, Owens, Leah, Kaufman, Laura, Arrowsmith, Edward, Patton, Jeffrey, Taylor, Jack L., Lyss, Aaron J., Kelsey, Carolyn J., Senneke, Kimberly, Frailley, Susan A

“…Abstract only 260 Background: The growing number of oral oncolytic therapies (OOTs) necessitates a standardized EMR workflow that integrates pharmacy…”
Get full text

Changes in adjuvant endocrine therapy over one year among postmenopausal women with early-stage breast cancer initiating aromatase inhibitors by LaMorte, Danielle Lindsay, Hartmann, Katherine E., Abramson, Vandana Gupta, Mayer, Ingrid A., Peacock, Nancy Walker, Cella, David, Castel, Liana Desharnais

“…Abstract only 11 Background: Aromatase inhibitors (AIs) are standard of care for adjuvant endocrine therapy (AET) to prevent recurrence of early stage breast…”
Get full text

Bevacizumab, pertuzumab, and sandostatin for patients (pts) with advanced neuroendocrine cancers (NET) by Firdaus, Irfan, Shih, Kent C., Zakari, Ahmed, Lang, Evan Z., McCleod, Michael, Alguire, Kathryn B., Peacock, Nancy Walker, Flora, Douglas B., Ruehlman, Peter, Earwood, Chris, Bendell, Johanna C.

“…Abstract only 4127 Background: Targeted agents are used to treat well-differentiated NET. Octreotide binds somatostatin receptors and improves time to…”
Get full text

Antiemetic guideline consistency and incidence of chemotherapy-induced nausea and vomiting (CINV) in U.S. community oncology practice: INSPIRE study by Gilmore, James W., Peacock, Nancy Walker, Gu, Anna, Szabo, Stephen, Rammage, Melissa, Sharpe, Joyce, Haislip, Sally, Perry, Toni S., Boozan, Tim Lee, Meador, Katherine, Cao, Xiting, Burke, Thomas A.

“…Abstract only 167 Background: Electronic Health Records (EHRs) are a valuable source to evaluate the quality of oncology care, particularly when combined with…”
Get full text

Everolimus with paclitaxel plus bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (MBC): A randomized, double-blind, placebo-controlled phase II trial of the Sarah Cannon Research Institute (SCRI) by Yardley, Denise Aysel, Bosserman, Linda D., Peacock, Nancy Walker, Favret, Anne, Morgan, Susan Kay, Priego, Victor M., Bass, J. David, Griner, Paula L., Burris, Howard A., Hainsworth, John D., O'Shaughnessy, Joyce

“…Abstract only 1018 Background: Constitutive activation of mTOR and amplified PI3K/Akt/mTOR signaling are common in MBC, and increase as treatment-resistance is…”
Get full text